2395 — Shin Nippon Biomedical Laboratories Income Statement
0.000.00%
Last trade - 00:00
- ¥59bn
- ¥73bn
- ¥25bn
- 68
- 58
- 31
- 52
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 15,659 | 14,561 | 15,111 | 17,748 | 25,091 |
Cost of Revenue | |||||
Gross Profit | 6,178 | 7,616 | 7,554 | 9,687 | 13,047 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 15,310 | 12,393 | 13,343 | 13,523 | 21,302 |
Operating Profit | 349 | 2,169 | 1,767 | 4,226 | 3,789 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1,651 | 3,063 | 4,176 | 8,183 | 7,760 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1,959 | 2,648 | 3,678 | 7,167 | 6,051 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 1,950 | 2,550 | 3,662 | 7,128 | 6,060 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1,950 | 2,550 | 3,662 | 7,128 | 6,060 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 46.3 | 62.5 | 77.8 | 148 | 174 |
Dividends per Share | |||||
Special Dividends per Share |